Your Subtype, Stage, and Ejection Fraction
At a Glance
Heart failure is described by ejection fraction, ACC/AHA stage, and NYHA functional class. EF shows how the heart pumps, stage reflects disease progression, and NYHA class reflects activity limits; an improved EF usually means remission, not a permanent cure.
When you are diagnosed with heart failure, your doctors will use several classification systems to describe exactly how your heart is working. These labels are not just “medical jargon”—they help your care team determine the most effective treatment for your specific situation.
Understanding Ejection Fraction (EF)
As mentioned in the diagnosis page, your medical team uses imaging like an echocardiogram to measure how well your heart pumps blood [1]. One important measure from this test is your Ejection Fraction (EF).
Think of your heart’s left ventricle as a glass of water. When the heart beats, it doesn’t empty completely. The EF is the percentage of blood that is pumped out of the ventricle with each contraction [2]. A normal EF typically ranges from roughly 55% to 70%. In heart failure, this number helps doctors categorize your condition into different subtypes [2][3]:
- HFrEF (Heart Failure with Reduced EF): Your EF is 40% or less. This means the heart muscle has weakened and cannot pump with enough force [2].
- HFmrEF (Heart Failure with Mildly Reduced EF): Your EF is between 41% and 49%. This is considered a middle ground where the heart’s pumping ability is slightly impaired [3].
- HFpEF (Heart Failure with Preserved EF): Your EF is 50% or higher. An EF in this range does not automatically mean you have HFpEF; the diagnosis requires matching symptoms alongside evidence of high filling pressures or congestion, indicating the heart is too stiff to fill properly [4][2].
- HFimpEF (Heart Failure with Improved EF): This describes a trajectory where a person previously had an EF of 40% or less, but after treatment, their EF improved to above 40% [2][5].
The “Remission” Concept: Why HFimpEF is Not a Permanent Cure
If your EF improves significantly, it is a major victory and a sign that your treatment is working. However, medical guidelines are very clear: improved EF reflects a state of remission or recovery, not a permanent cure [2][6].
The underlying vulnerabilities of the heart remain. Research shows that stopping medications can lead to a severe relapse. In one small study of patients who recovered from a specific type of dilated cardiomyopathy (the TRED-HF trial), roughly 40% relapsed within six months of stopping their medications [7]. Because of this risk, doctors generally recommend staying on your guideline-directed heart failure therapies indefinitely [8][9]. Always consult your doctor before making any medication changes.
Two Ways of Measuring Your Progress
Doctors use two different “staging” systems to track your heart failure. One looks at the physical progression of the disease, while the other looks at how you feel and function in daily life.
1. ACC/AHA Stages (The Structural Path)
This system (Stages A through D) tracks the progression of the disease itself. It helps doctors understand your medical history and the structural changes in your heart [10].
- Stage A: You are at high risk for heart failure (e.g., you have high blood pressure or diabetes) but have no structural heart issues and no symptoms [10].
- Stage B: You have structural heart disease (like a low EF or a thickened heart wall) but have never felt symptoms of heart failure [10].
- Stage C: You have structural heart disease and either currently have symptoms or have had them in the past [10]. Most people diagnosed with heart failure are in Stage C.
- Stage D: You have advanced heart failure that causes severe symptoms despite optimal treatments, and may require specialized interventions [10].
2. NYHA Functional Class (The Symptom Scale)
Unlike the stages above, your New York Heart Association (NYHA) Class can improve as treatment takes effect. This scale measures how much your symptoms limit your physical activity [11]. Your clinician will assign this class based on your usual routines and other health conditions.
| NYHA Class | What it Feels Like |
|---|---|
| Class I | No limitation. Ordinary physical activity (like walking or climbing stairs) does not cause fatigue or breathlessness [11]. |
| Class II | Mild limitation. You are comfortable at rest, but ordinary physical activity results in some fatigue or shortness of breath [11]. |
| Class III | Marked limitation. You are comfortable at rest, but less-than-ordinary physical activity (such as walking short distances) causes symptoms [11]. |
| Class IV | Severe limitation. You are unable to carry out any physical activity without discomfort, and you may feel symptoms even while resting [11]. |
By understanding both your stage and your class, you can better monitor your health. Your Stage tells you where you are in the overall journey of the disease, while your Class reflects how well your current treatment is helping you live your life [9][11].
Common questions in this guide
What does ejection fraction mean in heart failure?
Which heart failure subtype matches my EF?
Does an improved EF mean my heart failure is cured?
How is an ACC/AHA stage different from an NYHA class?
What do ACC/AHA stages A through D mean?
What do NYHA Classes I through IV describe?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my most recent echocardiogram, what is my exact ejection fraction (EF) percentage, and which subtype of heart failure do I have?
- 2.Since my EF has improved, am I now classified as having 'Heart Failure with Improved Ejection Fraction' (HFimpEF), and how does that change my long-term outlook?
- 3.Can you explain why I need to stay on my heart medications even if my EF has returned to a 'normal' range and I feel much better?
- 4.What is my current NYHA functional class, and what specific goals should we set to help me move to a more comfortable class?
- 5.Which ACC/AHA stage am I in, and what steps can we take to prevent me from progressing to the next stage?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (11)
- 1
Heart failure in the Portuguese population aged ≥50 years: prevalence and phenotypes in the PORTHOS study.
Baptista R, Rodrigues AM, Bernardo F, et al.
European heart journal 2026; doi:10.1093/eurheartj/ehag030.
PMID: 41641552 - 2
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association.
Bozkurt B, Coats AJS, Tsutsui H, et al.
European journal of heart failure 2021; (23(3)):352-380 doi:10.1002/ejhf.2115.
PMID: 33605000 - 3
Heart failure with mildly reduced ejection fraction: emerging frontiers in clinical characteristics, prognosis, and treatment.
Shang Z, Wang X, Gao W
Reviews in cardiovascular medicine 2022; (23(1)):30 doi:10.31083/j.rcm2301030.
PMID: 35092222 - 4
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.
Solomon SD, de Boer RA, DeMets D, et al.
European journal of heart failure 2021; (23(7)):1217-1225 doi:10.1002/ejhf.2249.
PMID: 34051124 - 5
Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure.
Savarese G, Vedin O, D'Amario D, et al.
JACC. Heart failure 2019; (7(4)):306-317 doi:10.1016/j.jchf.2018.11.019.
PMID: 30852236 - 6
Heart Failure With Improved Ejection Fraction: Is it Possible to Escape One's Past?
Gulati G, Udelson JE
JACC. Heart failure 2018; (6(9)):725-733 doi:10.1016/j.jchf.2018.05.004.
PMID: 30098965 - 7
Long-term follow-up of the TRED-HF trial: Implications for therapy in patients with dilated cardiomyopathy and heart failure remission.
Cheng L, Hammersley D, Ragavan A, et al.
European journal of heart failure 2025; (27(1)):113-123 doi:10.1002/ejhf.3475.
PMID: 39349993 - 8
Withdrawal of Spironolactone for Heart Failure With Improved Ejection Fraction: An Open-Label, Pilot, Randomized Controlled Trial (With-HF Trial).
Hyun J, Lee SA, Lee SE, et al.
Korean circulation journal 2025; (55(12)):1077-1089 doi:10.4070/kcj.2025.0052.
PMID: 40736394 - 9
Management of Heart Failure With Improved Ejection Fraction: Current Evidence and Controversies.
Kodur N, Tang WHW
JACC. Heart failure 2025; (13(4)):537-553 doi:10.1016/j.jchf.2025.02.007.
PMID: 40204384 - 10
Universal Definition and Classification of Heart Failure.
Bozkurt B, Coats A, Tsutsui H
Journal of cardiac failure 2021; doi:10.1016/j.cardfail.2021.01.022.
PMID: 33662581 - 11
An Observational Study of Evidence-Based Therapies in Older Patients with Heart Failure with Reduced Ejection Fraction: Insights from a Dedicated Heart Failure Clinic.
Araújo CS, Marco I, Restrepo-Córdoba MA, et al.
Journal of clinical medicine 2024; (13(23)) doi:10.3390/jcm13237171.
PMID: 39685630
This page is for informational purposes only and does not constitute medical advice. Your clinician should interpret your ejection fraction, heart failure stage, and NYHA class and guide any medication changes.
Get notified when new evidence is published on congestive heart failure.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.